didier frappaz
Centre Léon Bérard, Lyon · Centre Leon Berard
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Trials
Studies that name didier frappaz as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-12 11:58 UTC. Open this list on ClinicalTrials.gov
- Ph1/Ph2NCT01601184 · Study of Vismodegib in Combination With Temozolomide Versus Temozolomide Alone in Patients With Medulloblastomas With an Activation of the Sonic Hedgehog PathwayCentre Leon Berard · terminated · Histologically Confirmed Medulloblastoma, Activation of the Sonic Hedgehog (SHH) Pathway · principal investigator
- Ph3NCT00820963 · Standard Radiation Therapy, Higher-Dose Radiation Therapy, or Chemotherapy in Treating Older Patients With Glioblastoma MultiformeCentre Leon Berard · completed · Brain and Central Nervous System Tumors · unknown
- Ph2NCT00006119 · Hydroxyurea in Treating Patients With Recurrent and/or Unresectable MeningiomaUNICANCER · completed · Brain and Central Nervous System Tumors · study chair
Grants
NIH projects from RePORTER, fetched 2026-11-12 11:58 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. Coverage is US federal funding only; UK and EU funders are not searched yet.
No NIH project could be tied to this name by a shared trial or a matching institution.
Most cited trial papers
Clinical-trial papers with this author name in medulloblastoma, ranked by citations from NIH iCite, fetched 2026-11-12 11:58 UTC. The ranking covers the 200 most relevant of 6 PubMed records, and a shared surname and initials can bring in a namesake. All 6 on PubMed
- Treatment of medulloblastoma with postoperative chemotherapy alone: an SFOP prospective trial in young children.Lancet Oncol · 2005208 citationsRCR 5.2
- A phase I study of irinotecan as a 3-week schedule in children with refractory or recurrent solid tumors.J Clin Oncol · 200380 citationsRCR 1.9
- M4 protocol for cerebellar medulloblastoma: supratentorial radiotherapy may not be avoided.Int J Radiat Oncol Biol Phys · 199252 citationsRCR 1.8
- 37 citationsRCR 1.8
- 36 citationsRCR 1.0
- Phase II study of temozolomide and topotecan (TOTEM) in children with relapsed or refractory extracranial and central nervous system tumors including medulloblastoma with post hoc Bayesian analysis: A European ITCC study.Pediatr Blood Cancer · 202021 citationsRCR 1.0